Early stopping rules in oncology: considerations for clinicians

Area of Science:

• Oncology
• Clinical Trials
• Biostatistics

Background:

• The number of cancer clinical trials has significantly increased.
• Early termination of oncology studies due to benefit or harm is more frequent.
• Clinicians face challenges in integrating findings from early-stopped trials into practice.

Purpose of the Study:

• To explain the function of Data and Safety Monitoring Committees in trial cessation.
• To present examples of oncology trials that were stopped early.
• To review controversies and statistical concepts related to early stopping rules.

Main Methods:

• Review of literature on early stopping rules in clinical trials.
• Analysis of case examples of oncology trials stopped early.
• Discussion of statistical principles governing early trial termination.

Main Results:

• Data and Safety Monitoring Committees play a crucial role in trial oversight.
• Early stopping can occur for significant benefit or unforeseen harm.
• Statistical methods inform decisions regarding early trial cessation.

Conclusions:

• Interpreting early-stopped trials requires understanding specific statistical concepts.
• A practical approach is offered to aid clinicians in applying findings from these studies.
• This guidance assists in incorporating evidence from early-terminated trials into clinical decision-making.